Table 8.
Mouse (ICR) bone marrow micronucleus tests of the AstraZeneca MEK kinase inhibitor
| Agent | Dose (mg/kg) | MNPCE/1000 PCE |
% Centromere positive MN from experiment 2 |
||
|---|---|---|---|---|---|
| Experiment 1 (males) | Experiment 1a (females) | Experiment 2b (males) | |||
| Vehicle control | 0 | 0.4 | 0.5 | 1.15 | 10 |
| Test agent | 500 | 0.3 | 0.5 | 2.55c | 82 |
| 1000 | 0.7 | 0.5 | 3.28c | 74 | |
| 2000 | 2.5c | 2.9c | 2.72c | 39 | |
| CPA (positive control) | 50 | 19.3 | 21.5 | – | – |
| 65 | – | 27.5 | – | ||
All data is from bone marrows sampled 24 h after oral dosing (no effect at 48 h). PCE: polychromatic erythrocyte; MNPCE: micronucleated PCE; MN: micronuclei; CPA: cyclophosphamide.
Erythrocytes stained with May–Gruenwald–Giemsa.
Erythrocytes stained with Acridine Orange.
p < 0.05.